21 CFR 211.125
Strict control not exercised over labeling issued
- Inspections citing it: 467
- Of those classified, ended OAI: 22%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 211.125(a)
- 282 · Strict control not exercised over labeling issued
- 211.125(f)
- 130 · Procedures Written and Followed
- 211.125(c)
- 24 · Label reconciliation discrepancies evaluation/investigation
- 211.125(b)
- 19 · Examination of issued labels
- 211.125(d)
- 12 · Destruction of excess labels with lot numbers
Regulation Text
eCFR did not answer; open it on eCFRRecently Cited Sites
Newest inspections citing this section; each opens the site- Trifluent Pharma LLCUnited States · Jun 11, 2026
- Lantheus Medical Imaging, Inc.United States · Apr 9, 2026
- Dental Technologies, Inc.United States · Feb 10, 2026
- NexCell Scientific IncUnited States · Feb 5, 2026
- Medline Industries, LPUnited States · Jul 18, 2025
- Little Moon Essentials LLCUnited States · Jul 10, 2025
- Exel Inc.United States · Nov 25, 2024
- Mol Belting SystemsUnited States · Oct 29, 2024
- Qualgen, LLCUnited States · Mar 19, 2024
- Sina Health IncUnited States · Jan 13, 2023
- Lernapharm (Loris) Inc.Canada · May 6, 2022
- Illinois Tool Works IncUnited States · Apr 1, 2022
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR